SCHEMBL4097445

SCHEMBL4097445

Cc1ccc(Nc2cc(-c3cncnc3)ncn2)cc1NS(C)(=O)=O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 8/20 0.77
CDK9 P50750 5/20 0.70
CCNT1 O60563 3/20 0.70
CYP1A2 P05177 3/20 0.52
CYP3A4 P08684 3/20 0.52
CLK4 Q9HAZ1 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
USP2 O75604 1/20 0.52
CYP2D6 P10635 1/20 0.52
TSHR P16473 1/20 0.52
ABL1 P00519 1/20 0.49
BCR P11274 1/20 0.49
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
MAP4K4 O95819 1/20 0.44
CDK1 P06493 1/20 0.44
CDK4 P11802 1/20 0.44
CCNB1 P14635 1/20 0.44
CCND1 P24385 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4109321 0.87 BACE1 (1.00) BACE1CDK9CCNT1CYP1A2CYP3A4
SCHEMBL4108631 0.84 BACE1 (0.81) BACE1CDK9CCNT1CYP1A2CYP3A4
SCHEMBL4102091 0.83 BACE1 (0.77) BACE1CDK9CCNT1CYP1A2CYP3A4
SCHEMBL4103718 0.82 BACE1 (0.78) BACE1CDK9CCNT1CYP1A2CYP3A4
SCHEMBL4101898 0.82 CCNT1 (1.00) BACE1CDK9CCNT1CYP1A2CYP3A4
SCHEMBL4108736 0.82 BACE1 (0.81) BACE1CDK9CCNT1CYP1A2CYP3A4
SCHEMBL4097935 0.81 BACE1 (0.75) BACE1CDK9CCNT1CYP1A2CYP3A4
SCHEMBL4109256 0.81 BACE1 (0.79) BACE1CDK9CCNT1CYP1A2CYP3A4
SCHEMBL4098079 0.81 BACE1 (0.75) BACE1CDK9CCNT1CYP1A2CYP3A4
SCHEMBL4113685 0.80 BACE1 (0.74) BACE1CDK9CCNT1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221581-A1 Methods of treating pain ASTRAZENECA AB (SE) 2009-09-03 US claimed
US-8084457-B2 Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases LEAD DISCOVERY CENTER GMBH (DE) 2011-12-27 US disclosed
US-20090221581-A1 Methods of treating pain ASTRAZENECA AB (SE) 2009-09-03 US disclosed
US-20070191344-A1 Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191344-A1 Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases DAPK1, DUSP4, MARK4 BACE1 1494/4885CDK9 137/4885CCNT1 2075/4885
US-20090221581-A1 Methods of treating pain CDK5, CAMKK2, CDK3 BACE1 4371/4885CDK9 97/4885CCNT1 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.